


BioRestorative Therapies, Inc. (BRTX)

Nasdaq; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0001505497

BioRestorative Therapies, Inc. BRTX; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescans <i>split-adjusted close; the letter is fixed at the rescans that set it</i> 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$4.1M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, late filer, thin data not computable: distress, fortress balance sheet	
Inputs computable	6 of 14	
Graded from	filings received through Mar 26, 2026 197 days before the rescans; latest periodic filing 10-Q received May 14, 2026	
Last close	\$1.92 2026-10-08; market equity \$48.9M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A
B
C
D
E

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

used in this Annual Report on Form 10-K, or the Annual Report, references to the "Company", "we", "us", were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from "Stem Cell Assurance, Inc." to "BioRestorative Therapies, Inc." Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100. In March 2022, a United States patent issued in our Disc/Spine Program.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 44.2						
Gross profitability		8.2%	32.2%	78.4	372	2025-12-31

Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(42.2%)	(6.6%)	9.9	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 90.9						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-03-31
Altman Z double-prime		not computable	(0.31)			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31
Current ratio		0.84x	2.96x	90.9	839	2025-12-31
Growth and financing, sleeve percentile 67.1						
Revenue growth, three-year compound		44.3%	10.0%	15.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(37.2%)	2.1%	95.6	704	2025-12-31
Net share issuance, one year		239.5%	2.5%	90.7	634	2026-03-23

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 239.5%
Short runway	cash runway is 3.2 months
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	179.2%	8.0%	96
Distance from 52-week high	(58.2%)	(31.4%)	19
EBIT to enterprise value	(34.5%)	(1.5%)	18
Free cash flow yield	(22.6%)	(1.0%)	21
Book value to price	0.06	0.28	22
Sales to price	0.01	0.31	6
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.81	(0.14)	96

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$3.1M
Operating cash flow, four quarters	-\$11.8M
Months of runway	3.2
Days since last periodic filing	148 (10-Q received May 14, 2026)
Median daily dollar volume, 63 sessions	\$59,542

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$335,856	2025-12-31	2026-03-26	10-K	0001493152-26-012925
2	assets	us-gaap:Assets	\$4.1M	2025-12-31	2026-03-26	10-K	0001493152-26-012925
3	net income	us-gaap:NetIncomeLoss	-\$14.2M	2025-12-31	2026-03-26	10-K	0001493152-26-012925
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$10.8M	2025-12-31	2026-03-26	10-K	0001493152-26-012925
5	assets	us-gaap:Assets	\$12.3M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
6	current assets	us-gaap:AssetsCurrent	\$11.1M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
7	current liabilities	us-gaap:LiabilitiesCurrent	\$3.7M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$155.7M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
9	operating income	us-gaap:OperatingIncomeLoss	-\$11.6M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
10	book equity	us-gaap:StockholdersEquity	\$8.5M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
11	liabilities	us-gaap:Liabilities	\$3.7M	2024-12-31	2025-03-28	10-K	0001641172-25-001011
12	operating income	us-gaap:OperatingIncomeLoss	-\$7.2M	2015-12-31	2017-03-22	10-K	0001493152-17-002701
13	interest expense	us-gaap:InterestExpense	\$263,583	2015-12-31	2016-03-30	10-K	0001144204-16-091575
14	current assets	us-gaap:AssetsCurrent	\$3.1M	2025-12-31	2026-03-26	10-K	0001493152-26-012925
15	current liabilities	us-gaap:LiabilitiesCurrent	\$3.7M	2025-12-31	2026-03-26	10-K	0001493152-26-012925
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$359,700	2025-12-31	2026-03-26	10-K	0001493152-26-012925
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$401,000	2024-12-31	2026-03-26	10-K	0001493152-26-012925
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$145,800	2023-12-31	2025-03-28	10-K	0001641172-25-001011
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$119,800	2022-12-31	2024-06-11	10-K/A	0001493152-24-023479
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$116,069	2025-12-31	2026-03-26	10-K	0001493152-26-012925
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$8.2M	2024-12-31	2026-03-26	10-K	0001493152-26-012925
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$106,189	2024-12-31	2026-03-26	10-K	0001493152-26-012925
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.4M	2023-12-31	2025-03-28	10-K	0001641172-25-001011

24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$171,043	2023-12-31	2025-03-28	10-K	0001641172-25-001011
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.9M	2022-12-31	2024-06-11	10-K/A	0001493152-24-023479
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$265,223	2022-12-31	2024-06-11	10-K/A	0001493152-24-023479
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$408,069	2015-12-31	2017-03-22	10-K	0001493152-17-002701
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$213,784	2015-12-31	2017-03-22	10-K	0001493152-17-002701
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndLossFromEquityMethodInvestments	\$7.9M	2015-12-31	2017-03-22	10-K	0001493152-17-002701
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2015-12-31	2016-03-30	10-K	0001144204-16-091575
31	current assets	us-gaap:AssetsCurrent	\$289,278	2015-12-31	2017-03-22	10-K	0001493152-17-002701
32	current liabilities	us-gaap:LiabilitiesCurrent	\$5.6M	2015-12-31	2017-03-22	10-K	0001493152-17-002701
33	current assets	us-gaap:AssetsCurrent	\$114,313	2014-12-31	2016-03-30	10-K	0001144204-16-091575
34	current liabilities	us-gaap:LiabilitiesCurrent	\$8.5M	2014-12-31	2016-03-30	10-K	0001144204-16-091575
35	assets	us-gaap:Assets	\$12.6M	2023-12-31	2025-03-28	10-K	0001641172-25-001011
36	assets	us-gaap:Assets	\$16.4M	2022-12-31	2024-06-11	10-K/A	0001493152-24-023479
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,478,170	2026-03-23	2026-03-26	10-K	0001493152-26-012925
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,504,780	2025-03-26	2025-03-28	10-K	0001641172-25-001011